Revelation Biosciences (REVB) to Release Earnings on Friday

Revelation Biosciences (NASDAQ:REVB) is anticipated to post its quarterly earnings results before the market opens on Friday, March 28th. Analysts expect Revelation Biosciences to post earnings of ($3.20) per share for the quarter.

Revelation Biosciences Trading Down 1.4 %

Shares of NASDAQ REVB opened at $2.91 on Friday. The firm’s 50-day moving average price is $4.40 and its 200-day moving average price is $9.11. Revelation Biosciences has a 1-year low of $2.36 and a 1-year high of $60.80. The firm has a market capitalization of $2.63 million, a P/E ratio of -0.01 and a beta of 0.17.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.